drugset / Trial / NCT01549834

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

NCT01549834

Phase 2 Completed 434 enrolled AbbVie
RandomizedParallel-groupTriple-blindTreatment

Summary

This is an efficacy and safety study evaluating a new treatment for subjects with mild to moderate Alzheimer's disease.

Timeline

Start
2012-03
Primary completion
2013-10
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject ABT-126 Small molecule 25 mg
Subject ABT-126 Small molecule 75 mg

Indications